FindTrial
Sign In

Research on predicting the efficacy of neoadjuvant immunotherapy for locally advanced esophageal squamous cell carcinoma based on dual phase spectral CT multi parameter imaging

Research on predicting the efficacy of neoadjuvant immunotherapy for locally advanced esophageal squamous cell carcinoma based on dual phase spectral CT multi parameter imaging

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500114573
Enrollment
Unknown
Registered
2025-12-15
Start date
2026-01-01
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal squamous cell carcinoma

Interventions

Gold Standard:Pathological diagnosis
Index test:The AUC value of the efficacy prediction model is greater than 0.7

Sponsors

Zhejiang Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 79 Years

Inclusion criteria

Inclusion criteria: 1.Diagnosis of esophageal squamous cell carcinoma by endoscopic pathological biopsy before treatment, clinical stage T2-4NxM0; 2.The treatment plan is radical surgery after chemotherapy and immunotherapy; 3.Equipped with baseline and spectral CT enhanced scan SBI data package within two weeks prior to surgery; 4.Equipped with baseline and spectral CT enhanced scan SBI data package within two weeks prior to surgery;

Exclusion criteria

Exclusion criteria: 1.The patient has a history of other malignant tumors; 2.Changes in treatment plans due to various reasons; 3.The CT image quality is poor and cannot meet the analysis requirements;

Design outcomes

Primary

MeasureTime frame
TRG;Accuracy;—

Secondary

MeasureTime frame
Sensitivity;Specificity;—

Countries

China

Contacts

Public ContactGe Song

Zhejiang Cancer Hospital

applesong1985@sina.com+86 571 8812 2346

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026